The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives, 2927-71-1, formula is C4HCl2FN2, Name is 2,4-Dichloro-5-fluoropyrimidine. including the nucleotides cytosine, thymine and uracil, thiamine (vitamin B1) and alloxan. Quality Control of 2927-71-1.
Fensome, Andrew;Ambler, Catherine M.;Arnold, Eric;Banker, Mary Ellen;Brown, Matthew F.;Chrencik, Jill;Clark, James D.;Dowty, Martin E.;Efremov, Ivan V.;Flick, Andrew;Gerstenberger, Brian S.;Gopalsamy, Ariamala;Hayward, Matthew M.;Hegen, Martin;Hollingshead, Brett D.;Jussif, Jason;Knafels, John D.;Limburg, David C.;Lin, David;Lin, Tsung H.;Pierce, Betsy S.;Saiah, Eddine;Sharma, Raman;Symanowicz, Peter T.;Telliez, Jean-Baptiste;Trujillo, John I.;Vajdos, Felix F.;Vincent, Fabien;Wan, Zhao-Kui;Xing, Li;Yang, Xiaojing;Yang, Xin;Zhang, Liying research published 《 Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)》, the research content is summarized as follows. Cytokine signaling is an important characteristic of autoimmune diseases. Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway. JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6 and type-I interferon (IFN) family, while TYK2 in addition to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling. Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease and rheumatoid arthritis studies, leading to multiple drug approvals. It is hypothesized that a dual JAK1/TYK2 inhibitor will provide addnl. efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes. Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compound 23), which is in Phase II clin. development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).
Quality Control of 2927-71-1, 2,4-Dichloro-5-fluoropyrimidine is a useful research compound. Its molecular formula is C4HCl2FN2 and its molecular weight is 166.97 g/mol. The purity is usually 95%.
2,4-Dichloro-5-fluoropyrimidine is an aromatic hydrocarbon that has been shown to inhibit the growth of mouse tumor cells in vitro. It also inhibits the production of amines by reacting with industrial chemicals and sodium carbonate. This compound has potent inhibitory activity against autoimmune diseases and cytotoxic potency on mcf-7 cells. Furthermore, 2,4-Dichloro-5-fluoropyrimidine has been shown to have a chlorinating effect on cancer cells., 2927-71-1.
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia